Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.
- DOI
- 10.1093/infdis/jiae530
- Published
- 2025-03-01
- Container
- J Infect Dis
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/infdis/jiae530,
title = {Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.},
author = {Bailón L and Puertas MC and García-Guerrero MC and Moraes-Cardoso I and Aparicio E and Alarcón-Soto Y and Rivero A and Rosen EP and Estes JD and Blanco J and Olvera A and Mothe B and Martinez-Picado J and Moltó J and DUALITY Study Group
.},
year = {2025},
journal = {J Infect Dis},
doi = {10.1093/infdis/jiae530},
url = {https://doi.org/10.1093/infdis/jiae530}
}RIS
TY - JOUR TI - Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. AU - Bailón L AU - Puertas MC AU - García-Guerrero MC AU - Moraes-Cardoso I AU - Aparicio E AU - Alarcón-Soto Y AU - Rivero A AU - Rosen EP AU - Estes JD AU - Blanco J AU - Olvera A AU - Mothe B AU - Martinez-Picado J AU - Moltó J AU - DUALITY Study Group . PY - 2025 JO - J Infect Dis DO - 10.1093/infdis/jiae530 UR - https://doi.org/10.1093/infdis/jiae530 ER -
APA
L, B., MC, P., MC, G., I, M., E, A., Y, A., A, R., EP, R., JD, E., J, B., A, O., B, M., J, M., J, M., & ., D. S. G. (2025). Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.. J Infect Dis. https://doi.org/10.1093/infdis/jiae530
Source records
- europe-pmc · retrieved 2026-09-27T02:01:12.567Z